1. Science magazine's association with his recurring "editorially independent blog". I've been a subscriber for many years and have never enjoyed it personally.
2. His opinion on this topic in general. The drug lived up to the hype even beating some international antivirals on efficacy terms.
Today's science is a bit further ahead still. For example, Pfizer will publish acute 10d data soon? which already has preliminary data showing faster symptom resolution and less rebound.
NIH/Yale/Karolinska will publish their 25d/15d/15d Long COVID Paxlovid studies to see what phenotypes may benefit from extended durations.
1. Science magazine's association with his recurring "editorially independent blog". I've been a subscriber for many years and have never enjoyed it personally.
2. His opinion on this topic in general. The drug lived up to the hype even beating some international antivirals on efficacy terms.
Today's science is a bit further ahead still. For example, Pfizer will publish acute 10d data soon? which already has preliminary data showing faster symptom resolution and less rebound.
NIH/Yale/Karolinska will publish their 25d/15d/15d Long COVID Paxlovid studies to see what phenotypes may benefit from extended durations.
And next gen Paxlovid is already on an accelerated approval path and showed great results at IDWeek. https://clinicaltrials.gov/study/NCT06679140#study-plan
It is odd to me because he even wrote a piece about the next gen Paxlovid? Why didn't he reference it! It's in phase 3... https://www.science.org/content/blog-post/next-paxlovid